LONDON – Having become popular with both celebrities and investors, diabetes drugs that also promote weight loss, such as Novo Nordisk’s Ozempic, are now being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer’s disease.
Diabetes regimens,…
Source: www.japantimes.co.jp – Read more
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
